LBA2 Phase II study of PD-L1 expression guidance on neoadjuvant (NA) nivolumab (Nivo) monotherapy with or without platinum-doublet chemotherapy in resectable NSCLC

Liu, S.-Y.; Dong, S.; Liao, Ruixue; Zhang, J.-T.; Lin, J.-T.; Zhang, S.; Yang, J.; Nie, Q.; X., Yang,; Wang, Q.; Yan, H.-H.; Yan, L.; Tu, H.; Wang, B.-C.; Yang, J.-J.; Zhou, Q.; Liu, S.-Y.M.; Zhong, W.-Z.; Wu, Y.-L.

doi:10.1016/j.iotech.2022.100363

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the appropriate neoadjuvant chemoimmunotherapy combination for resectable NSCLC has been investigated. Presented at the European Society of Medical Oncology (ESMO) in 2022, a phase II study showed that chemotherapy + nivolumab produced significantly better response rates than nivolumab alone, even in the PD-L1 high population (complete and major pathological response rates were 50% and 80% versus 18.2%, respectively) [63]. Consistent with our observation, chemotherapy was indeed required for a better response when combined with an anti-PD-1 mAb.…”

Section: Discussionsupporting

confidence: 87%

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in efficacy. In the absence of head-to-head randomized control trials (RCTs), we utilized network meta-analysis (NWM) to provide an indirect comparison of their efficacy. A systematic literature review and NWM were performed using RCTs that investigated anti-PD-1 or PD-L1 mAbs ± chemotherapy in patients with mNSCLC in the first-line setting. The primary outcome was comparative overall survival (OS), while secondary outcomes were comparative progression-free survival (PFS), objective response rate (ORR), and rate of grade 3 and higher toxicities. We identified 24 RCTs. Patients treated with anti-PD-1 mAb + chemotherapy compared with anti-PD-L1 mAb + chemotherapy showed superior mOS, mPFS, and ORR with a similar rate of grade 3 and higher toxicities. This difference in mOS was most pronounced in the PD-L1 TPS 1–49% population. The two mAbs were equivalent as single agents. Anti-PD-1 mAb + chemotherapy improved mOS when compared to anti-PD-1 mAb monotherapy, whereas anti-PD-L1 mAbs + chemotherapy did not when compared to anti-PD-L1 mAb monotherapy. Head-to-head RCTs are warranted in the future.

show abstract

Section: Discussionsupporting

confidence: 87%

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The result showed that OS was 90% for patients treated with neoadjuvant ICI therapy and 67% for patients treated with adjuvant ICI therapy at a median follow-up time of 32 months ( 234 ). At the European Society of Internal Oncology Immunooncology Conference in 2022, a phase II CA209-8D8 study of neoadjuvant therapy for NSCLC based on nivolumab, led by Professor Wu Yilong (Guangdong Provincial People's Hospital, Guangzhou, China), also announced the advantages of neoadjuvant immunotherapy ( 237 ). Specifically, patients can benefit from nivolumab + chemotherapy regardless of PD-L1 expression, and the neoadjuvant therapy does not affect the timing and feasibility of surgery, nor does it increase the difficulty of surgery ( 237 ).…”

Section: Combination Of Icis With Other Therapeutic Strategiesmentioning

confidence: 99%

“…At the European Society of Internal Oncology Immunooncology Conference in 2022, a phase II CA209-8D8 study of neoadjuvant therapy for NSCLC based on nivolumab, led by Professor Wu Yilong (Guangdong Provincial People's Hospital, Guangzhou, China), also announced the advantages of neoadjuvant immunotherapy ( 237 ). Specifically, patients can benefit from nivolumab + chemotherapy regardless of PD-L1 expression, and the neoadjuvant therapy does not affect the timing and feasibility of surgery, nor does it increase the difficulty of surgery ( 237 ). However, further investigations into the optimal duration of neoadjuvant immunotherapy and surgery, the optimal type of immunotherapy, and the efficacy and safety of neoadjuvant immunotherapy are required.…”

Section: Combination Of Icis With Other Therapeutic Strategiesmentioning

confidence: 99%

New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)

et al. 2023

View full text Add to dashboard Cite

The use of immune checkpoint inhibitors (ICIs) has been demonstrated in the treatment of numerous types of cancer and ICIs have remained a key focus of cancer research. However, improvements in survival rates only occur in a subset of patients, due to the complexity of drug resistance. Therefore, further investigations are required to identify predictive biomarkers that distinguish responders and non-responders. Combined therapeutics involving ICIs and other modalities demonstrate potential in overcoming resistance to ICIs; however, further preclinical and clinical trials are required. Concurrently, prompt recognition and intervention of immune-related adverse events are crucial to optimize the use of ICIs in clinical treatment. The present study aimed to review the current literature surrounding the mechanisms and application of ICIs, with the aim of providing a theoretical basis for clinicians.

show abstract

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

Maggie Liu,

Huang,

Deng

et al. 2024

Science Bulletin

View full text Add to dashboard Cite

LBA2 Phase II study of PD-L1 expression guidance on neoadjuvant (NA) nivolumab (Nivo) monotherapy with or without platinum-doublet chemotherapy in resectable NSCLC

Cited by 3 publications

References 0 publications

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

Contact Info

Product

Resources

About